General information about Sibutramine in the UK
An agent for treating obesity central action. The mechanism of action caused by a selective serotonin reuptake inhibition and norepinephrine, to a lesser extent - dopamine. It accelerates the onset and prolongs the feeling of satiety, which reduces the consumption of food. It increases energy expenditure by stimulating thermogenesis mediated by the activation of β3-adrenergic receptors. It acts on both sides of the energy balance and helps to reduce body weight.
Sibutramine and its metabolites do not release and are monoamines MAO inhibitors, do not have an affinity for serotonergic, adrenergic, dopaminergic, muscarinic, histamine, NMDA receptors and benzodiazepine.
As part of supporting the complex therapy of patients with overweight with alimentary obesity with a body mass index of 30 kg / m2 or more, with alimentary obesity index of 27 kg / m2 body mass or more in the presence of other risk factors arising from overweight, including type 2 diabetes mellitus (insulin-dependent) and hyperlipidemia.
The initial dose is 10 mg / day. In inefficiency when used in this dose (weight loss less than 2 kg for 4 weeks), and if tolerated dose can be increased to 15 mg / day.
If no effect when applied in a dose of 15 mg / day (weight loss less than 2 kg for 4 weeks) sibutramine should be canceled.
Patients not adequately responsive to therapy in the UK, i.e. who for 3 months can not reach the level of 5% reduction in body weight from baseline, duration of application should not exceed 3 months.
The course of treatment is not more than 1 year since no data on the efficacy and safety of a prolonged use.
Do not continue to use, if after achieved weight loss in the course of further treatment, the patient re-gaining weight 3 kg or more.